| Detailed information |
|---|
| CancerLivER ID | 2106 |
| Biomarker | TOPO2 |
| Biomarker Name/Symbol (given in Publication) | TOPO II |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Biomarker for advanced hepatocellular carcinoma patient receiving chemotherapeutics; but not validated on independent dataset |
| Experimental Condition | Normal vs HCC |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in nucleolus of HCC |
| Level of significance | NA |
| Source | Tissue |
| PMID | 26722553 |
| Type of Biomarker | Diagnostic |
| Pathway | apoptosis-associated with p53 pathway |
| Cohort | 4 advanced liver cancer patients who recieved chemotherapy |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2015 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |